These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

1706 related items for PubMed ID: 32962206

  • 1. High Sensitivity of Circulating Tumor Cells Derived from a Colorectal Cancer Patient for Dual Inhibition with AKT and mTOR Inhibitors.
    Smit DJ, Cayrefourcq L, Haider MT, Hinz N, Pantel K, Alix-Panabières C, Jücker M.
    Cells; 2020 Sep 20; 9(9):. PubMed ID: 32962206
    [Abstract] [Full Text] [Related]

  • 2. Functional characterization of PI3K C2 domain mutations detected in breast cancer circulating tumor cells and metastatic cells.
    Smit DJ, Brauer H, Horn S, Yigit G, Haider MT, Pogenberg V, Schumacher U, Pantel K, Jücker M.
    Cell Signal; 2024 Sep 20; 121():111270. PubMed ID: 38909932
    [Abstract] [Full Text] [Related]

  • 3. Combined targeting of AKT and mTOR synergistically inhibits proliferation of hepatocellular carcinoma cells.
    Grabinski N, Ewald F, Hofmann BT, Staufer K, Schumacher U, Nashan B, Jücker M.
    Mol Cancer; 2012 Nov 20; 11():85. PubMed ID: 23167739
    [Abstract] [Full Text] [Related]

  • 4. Combined targeting of AKT and mTOR using MK-2206 and RAD001 is synergistic in the treatment of cholangiocarcinoma.
    Ewald F, Grabinski N, Grottke A, Windhorst S, Nörz D, Carstensen L, Staufer K, Hofmann BT, Diehl F, David K, Schumacher U, Nashan B, Jücker M.
    Int J Cancer; 2013 Nov 20; 133(9):2065-76. PubMed ID: 23588885
    [Abstract] [Full Text] [Related]

  • 5. Dual mTOR/PI3K inhibitor NVP‑BEZ235 arrests colorectal cancer cell growth and displays differential inhibition of 4E‑BP1.
    Alqurashi N, Hashimi SM, Alowaidi F, Ivanovski S, Wei MQ.
    Oncol Rep; 2018 Aug 20; 40(2):1083-1092. PubMed ID: 29845289
    [Abstract] [Full Text] [Related]

  • 6. Combined Targeting of AKT and mTOR Synergistically Inhibits Formation of Primary Colorectal Carcinoma Tumouroids In Vitro: A 3D Tumour Model for Pre-therapeutic Drug Screening.
    Nörz D, Mullins CS, Smit DJ, Linnebacher M, Hagel G, Mirdogan A, Siekiera J, Ehm P, Izbicki JR, Block A, Thastrup O, Jücker M.
    Anticancer Res; 2021 May 20; 41(5):2257-2275. PubMed ID: 33952452
    [Abstract] [Full Text] [Related]

  • 7. Antitumor activity of pimasertib, a selective MEK 1/2 inhibitor, in combination with PI3K/mTOR inhibitors or with multi-targeted kinase inhibitors in pimasertib-resistant human lung and colorectal cancer cells.
    Martinelli E, Troiani T, D'Aiuto E, Morgillo F, Vitagliano D, Capasso A, Costantino S, Ciuffreda LP, Merolla F, Vecchione L, De Vriendt V, Tejpar S, Nappi A, Sforza V, Martini G, Berrino L, De Palma R, Ciardiello F.
    Int J Cancer; 2013 Nov 20; 133(9):2089-101. PubMed ID: 23629727
    [Abstract] [Full Text] [Related]

  • 8. Probing the PI3K/Akt/mTor pathway using 31P-NMR spectroscopy: routes to glycogen synthase kinase 3.
    Phyu SM, Tseng CC, Fleming IN, Smith TA.
    Sci Rep; 2016 Nov 04; 6():36544. PubMed ID: 27811956
    [Abstract] [Full Text] [Related]

  • 9. Dual PI3K/mTOR inhibition shows antileukemic activity in MLL-rearranged acute myeloid leukemia.
    Sandhöfer N, Metzeler KH, Rothenberg M, Herold T, Tiedt S, Groiß V, Carlet M, Walter G, Hinrichsen T, Wachter O, Grunert M, Schneider S, Subklewe M, Dufour A, Fröhling S, Klein HG, Hiddemann W, Jeremias I, Spiekermann K.
    Leukemia; 2015 Apr 04; 29(4):828-38. PubMed ID: 25322685
    [Abstract] [Full Text] [Related]

  • 10. Dual inhibition of the PI3K/AKT/mTOR pathway suppresses the growth of leiomyosarcomas but leads to ERK activation through mTORC2: biological and clinical implications.
    Fourneaux B, Chaire V, Lucchesi C, Karanian M, Pineau R, Laroche-Clary A, Italiano A.
    Oncotarget; 2017 Jan 31; 8(5):7878-7890. PubMed ID: 28002802
    [Abstract] [Full Text] [Related]

  • 11. K-Ras mutation and amplification status is predictive of resistance and high basal pAKT is predictive of sensitivity to everolimus in biliary tract cancer cell lines.
    Yeung Y, Lau DK, Chionh F, Tran H, Tse JWT, Weickhardt AJ, Nikfarjam M, Scott AM, Tebbutt NC, Mariadason JM.
    Mol Oncol; 2017 Sep 31; 11(9):1130-1142. PubMed ID: 28544747
    [Abstract] [Full Text] [Related]

  • 12. Effects of Glut1 gene silencing on proliferation, differentiation, and apoptosis of colorectal cancer cells by targeting the TGF-β/PI3K-AKT-mTOR signaling pathway.
    Wu XL, Wang LK, Yang DD, Qu M, Yang YJ, Guo F, Han L, Xue J.
    J Cell Biochem; 2018 Feb 31; 119(2):2356-2367. PubMed ID: 28884839
    [Abstract] [Full Text] [Related]

  • 13. Targeting PI3K/mTOR overcomes resistance to HER2-targeted therapy independent of feedback activation of AKT.
    O'Brien NA, McDonald K, Tong L, von Euw E, Kalous O, Conklin D, Hurvitz SA, di Tomaso E, Schnell C, Linnartz R, Finn RS, Hirawat S, Slamon DJ.
    Clin Cancer Res; 2014 Jul 01; 20(13):3507-20. PubMed ID: 24879796
    [Abstract] [Full Text] [Related]

  • 14. Synthetic lethal interaction between PI3K/Akt/mTOR and Ras/MEK/ERK pathway inhibition in rhabdomyosarcoma.
    Guenther MK, Graab U, Fulda S.
    Cancer Lett; 2013 Sep 01; 337(2):200-9. PubMed ID: 23684925
    [Abstract] [Full Text] [Related]

  • 15. Inhibition of autophagy enhances apoptosis induced by the PI3K/AKT/mTor inhibitor NVP-BEZ235 in renal cell carcinoma cells.
    Li H, Jin X, Zhang Z, Xing Y, Kong X.
    Cell Biochem Funct; 2013 Jul 01; 31(5):427-33. PubMed ID: 23086777
    [Abstract] [Full Text] [Related]

  • 16. Loss of fatty acid synthase suppresses the malignant phenotype of colorectal cancer cells by down-regulating energy metabolism and mTOR signaling pathway.
    Chang L, Wu P, Senthilkumar R, Tian X, Liu H, Shen X, Tao Z, Huang P.
    J Cancer Res Clin Oncol; 2016 Jan 01; 142(1):59-72. PubMed ID: 26109148
    [Abstract] [Full Text] [Related]

  • 17. Exclusive inhibition of PI3K/Akt/mTOR signaling is not sufficient to prevent PDGF-mediated effects on glycolysis and proliferation in colorectal cancer.
    Moench R, Grimmig T, Kannen V, Tripathi S, Faber M, Moll EM, Chandraker A, Lissner R, Germer CT, Waaga-Gasser AM, Gasser M.
    Oncotarget; 2016 Oct 18; 7(42):68749-68767. PubMed ID: 27626684
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Vertical blockade of the IGFR- PI3K/Akt/mTOR pathway for the treatment of hepatocellular carcinoma: the role of survivin.
    Ou DL, Lee BS, Lin LI, Liou JY, Liao SC, Hsu C, Cheng AL.
    Mol Cancer; 2014 Jan 03; 13():2. PubMed ID: 24387108
    [Abstract] [Full Text] [Related]

  • 20. Single Agent and Synergistic Activity of the "First-in-Class" Dual PI3K/BRD4 Inhibitor SF1126 with Sorafenib in Hepatocellular Carcinoma.
    Singh AR, Joshi S, Burgoyne AM, Sicklick JK, Ikeda S, Kono Y, Garlich JR, Morales GA, Durden DL.
    Mol Cancer Ther; 2016 Nov 03; 15(11):2553-2562. PubMed ID: 27496136
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 86.